Accéder au contenu
Merck

Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.

Future oncology (London, England) (2013-11-15)
Nicoletta Colombo
RÉSUMÉ

Ovarian cancer is the leading cause of gynecological cancer deaths worldwide. Despite primary treatment with platinum-containing regimens, the majority of women will experience recurrent disease and subsequent death. Recurrent ovarian cancer remains a challenge for successful management, and the choice of second-line chemotherapy is complex due to the range of different factors that need to be considered. One of the main considerations is the platinum-free interval and, specifically, the optimal treatment for patients who are partially platinum-sensitive (platinum-free interval: 6-12 months). Data from the large, multicenter, randomized OVA-301 study have shown that combined trabectedin-pegylated liposomal doxorubicin (PLD) significantly prolonged median overall survival compared with PLD alone (p = 0.0027) in 214 patients with partially platinum-sensitive advanced relapsed ovarian cancer. Furthermore, in OVA-301 patients with partially platinum-sensitive disease who received platinum therapy immediately after disease progression (n = 94), final median overall survival was improved by 9 months (p = 0.0153) in trabectedin-PLD patients compared with PLD alone. In addition to demonstrating a survival advantage, trabectedin-PLD may also allow the treatment of patients having not yet recovered from previous platinum toxicity. In summary, the data suggest the use of combined trabectedin-PLD as a second-line treatment option in patients with partially platinum-sensitive recurrent ovarian cancer, followed by a third-line platinum-containing regimen.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Platinum, gauze, 100 mesh, 99.9% trace metals basis
Sigma-Aldrich
Platinum black, black, powder, ≤20 μm, ≥99.95% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 1.0 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.5 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, foil, thickness 0.025 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, powder, 99.995% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.25 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.5 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, gauze, 52 mesh, 99.9% trace metals basis
Sigma-Aldrich
Platinum, nanopowder, <50 nm particle size (TEM)
Sigma-Aldrich
Platinum black, fuel cell grade, ≥99.9% trace metals basis
Sigma-Aldrich
Platinum, foil, thickness 0.05 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 2.0 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.10 mm, 99.99% trace metals basis
Platinum, wire reel, 1m, diameter 0.5mm, as drawn, 99.99+%
Sigma-Aldrich
Platinum black, low bulk density, ≥99.9% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.25 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, nanopowder, 200 nm particle size (SEM), 99.9% (metals basis)
Platinum, foil, not light tested, 100x100mm, thickness 0.0125mm, as rolled, 99.95%
Sigma-Aldrich
Platinum, foil, thickness 0.25 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.25 mm, thermocouple grade
Sigma-Aldrich
Platinum, foil, thickness 1.0 mm, 99.99% trace metals basis
Platinum, wire reel, 0.5m, diameter 0.5mm, as drawn, 99.99+%
Sigma-Aldrich
Platinum, wire, diam. 0.127 mm, 99.99% trace metals basis
Platinum, tube, 100mm, outside diameter 0.95mm, inside diameter 0.60mm, wall thickness 0.175mm, as drawn, 99.95%
Sigma-Aldrich
Platinum, powder (coarse), 99.99% trace metals basis
Platinum, wire reel, 10m, diameter 0.025mm, hard, 99.9%
Platinum, foil, 25x25mm, thickness 0.25mm, as rolled, 99.95%
Platinum, rod, 200mm, diameter 1.0mm, 99.95%
Platinum, foil, 25x25mm, thickness 0.1mm, as rolled, 99.99+%